Surgically‐related severe adverse effects (grade 3+) ‐ postoperative G3+ events (within 30 days of surgery) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ postoperative… compared with surgery followed by chemotherapy (PDS) (moderate certainty).
1 finding from 1 review
Adverse events · people with single or solitary brain metastasis
It is very uncertain whether surgery plus whole brain radiotherapy (WBRT) changes adverse events compared with stereotactic radiosurgery (very low certainty).
1 finding from 1 review
Adverse events · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Adverse events · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Adverse events (severe) · people with single or solitary brain metastasis
It is very uncertain whether surgery plus whole brain radiotherapy (WBRT) changes adverse events (severe) compared with stereotactic radiosurgery (very low certainty).
1 finding from 1 review
Adverse events · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Adverse events (moderate) · people with single or solitary brain metastasis
It is very uncertain whether surgery plus whole brain radiotherapy (WBRT) changes adverse events (moderate) compared with stereotactic radiosurgery (very low certainty).
1 finding from 1 review
Adverse events (moderate) · people with single or solitary brain metastasis
It is very uncertain whether surgery plus whole brain radiotherapy (WBRT) changes adverse events (moderate) compared with stereotactic radiosurgery plus WBRT (very low certainty).
1 finding from 1 review
Adverse events (acute complication after surgery)
It is very uncertain whether suprapubic catheterisation changes adverse events (acute complication after surgery) compared with intermittent self‐catheterisation (very low certainty).
1 finding from 1 review
Severe adverse events · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a diagnosis of brain…
1 finding from 1 review
Severe adverse events · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a diagnosis of brain…
1 finding from 1 review
Intervention not reported
Adverse events · women with stage I/II epithelial ovarian cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events · Patients with brain metastases
1 finding from 1 review
Adverse events: lymphoedema · women (18 years and older) diagnosed with stage IB2 cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (range of outcomes) · adult women diagnosed with early stage (I to IIa) endometrial cancer undergoing surgery as primary treatment.
Laparoscopy showed no clear difference in serious adverse events (range of outcomes) compared with laparotomy (low certainty).
1 finding from 1 review
Intervention not reported
Genitourinary adverse events (grade 3 or 4) · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA)
The intervention showed no clear difference in genitourinary adverse events (grade 3 or 4) (moderate certainty).
1 finding from 1 review
Intervention not reported
Haematological adverse events (grade 3 or 4) · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA)
The intervention showed no clear difference in haematological adverse events (grade 3 or 4) (moderate certainty).
1 finding from 1 review
Intervention not reported
Gastrointestinal adverse events (grade 3 or 4) · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA)
The intervention showed no clear difference in gastrointestinal adverse events (grade 3 or 4) (moderate certainty).
1 finding from 1 review